Ozempic vs. Wegovy vs. Mounjaro vs. Zepbound: How they differ

If you've heard the names Ozempic, Wegovy, Mounjaro, and Zepbound mentioned in the same breath, you're not alone in wondering how they differ. All four medications have reshaped conversations about weight loss and diabetes treatment over the past several years — yet many people are surprised to learn that the drugs come in just two active ingredients. Understanding which drug does what, how each works in the body, and what separates them on cost and eligibility can help you have a more informed conversation with your provider.

The brand-to-ingredient map

The simplest way to understand these four drugs is to group them by active ingredient. Semaglutide is the molecule behind both Ozempic and Wegovy. Tirzepatide is the molecule behind both Mounjaro and Zepbound. The brand names differ because the FDA approves drugs for specific indications — not just ingredients — and the two formulations of each drug target different patient populations.

• Ozempic (semaglutide) — FDA-approved for type 2 diabetes management and cardiovascular risk reduction in adults with type 2 diabetes and established heart disease. Maximum weekly dose: 2 mg.
• Wegovy (semaglutide) — FDA-approved for chronic weight management in adults with a BMI of 30 or higher, or 27 or higher with at least one weight-related condition. Maximum weekly dose: 2.4 mg.
• Mounjaro (tirzepatide) — FDA-approved for type 2 diabetes management. Maximum weekly dose: 15 mg.
• Zepbound (tirzepatide) — FDA-approved for chronic weight management, with the same BMI criteria as Wegovy. Maximum weekly dose: 15 mg.

Both pairs are administered as once-weekly subcutaneous injections, and both use a gradual dose-escalation schedule to reduce gastrointestinal side effects during the first several months of treatment.

How these drugs work in the body

Semaglutide belongs to a class called GLP-1 receptor agonists. GLP-1 (glucagon-like peptide-1) is a hormone naturally released in the gut after eating. It stimulates insulin secretion, suppresses glucagon, slows gastric emptying, and signals the brain's satiety centers. By mimicking this hormone, semaglutide improves blood sugar control and reduces appetite.

Tirzepatide goes a step further. It is a dual GIP and GLP-1 receptor agonist — meaning it activates both the GLP-1 pathway and the GIP (glucose-dependent insulinotropic polypeptide) pathway simultaneously. GIP is another gut-derived hormone with its own effects on insulin release and fat metabolism. The addition of GIP receptor activity is believed to be one reason tirzepatide tends to produce greater average weight loss than semaglutide in head-to-head and comparative studies.

In the SURMOUNT-1 trial, participants taking the highest dose of tirzepatide (15 mg) lost an average of 22.5% of their body weight over 72 weeks. In the STEP 1 trial of semaglutide at 2.4 mg, participants lost approximately 14.9% of body weight over 68 weeks. Both results are substantially larger than what was seen with older weight-loss medications, but the gap between the two drugs is clinically meaningful for many patients.

Safety considerations and the black-box warning

All four medications carry the same FDA black-box warning — the most serious type — regarding the potential risk of thyroid C-cell tumors. This warning is based on animal studies in rodents, and it has not been confirmed in humans. However, people with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) should not take any of these medications.

Common side effects across all four drugs include nausea, vomiting, diarrhea, constipation, and abdominal pain — particularly during dose escalation. More serious but rare risks include pancreatitis, gallbladder disease, and kidney injury (often secondary to dehydration from gastrointestinal symptoms). Patients are typically counseled to eat smaller meals, avoid high-fat foods, and stay well hydrated, especially early in treatment.

Because both Ozempic and Mounjaro are indicated for diabetes, prescribing them for weight loss in people without diabetes is considered off-label use. Insurance coverage often depends on the specific indication listed on the prescription, which is one reason cost can vary so dramatically from patient to patient.

Cost and access

Without insurance, all four medications carry list prices that can exceed $900–$1,300 per month, putting them out of reach for many patients. Manufacturer savings programs — Novo Nordisk's savings card for Wegovy and Eli Lilly's savings card for Zepbound — can significantly reduce out-of-pocket costs for commercially insured patients, but often don't apply to Medicare or Medicaid beneficiaries.

The rise of compounding pharmacies offering semaglutide and tirzepatide at lower prices has expanded access, but the FDA has raised concerns about quality control in compounded formulations. Reported issues include dosing errors, contamination, and the use of salt forms of semaglutide that may not behave identically to the FDA-approved base form. Anyone considering a compounded GLP-1 medication should discuss the risks with their prescribing provider and confirm the pharmacy's accreditation status.

Insurance coverage for weight-loss indications (Wegovy and Zepbound) remains inconsistent. Many employer-sponsored plans have added coverage as evidence of cardiovascular benefit has grown — the SELECT trial demonstrated that semaglutide reduced major cardiovascular events in non-diabetic people with obesity — but coverage gaps remain common.

Choosing between them

The decision between semaglutide and tirzepatide is rarely made by the patient alone. Providers consider your primary diagnosis (diabetes vs. weight management), insurance formulary, tolerance of side effects, and your weight-loss goals. For patients whose primary concern is blood sugar control, either Ozempic or Mounjaro may be appropriate. For patients primarily focused on weight reduction and who have not responded well to semaglutide, tirzepatide may offer a meaningful advantage.

Neither drug is a substitute for lifestyle changes. Both are intended to be used alongside a reduced-calorie diet and increased physical activity, and the best outcomes in clinical trials were seen in participants who maintained those behaviors throughout treatment.

When to visit urgent care

If you experience severe abdominal pain, persistent vomiting, signs of low blood sugar, or an allergic reaction while taking any of these medications, visit a nearby urgent care clinic for same-day evaluation. Urgent care can also help if you have questions about starting or managing a GLP-1 medication and cannot get a timely appointment with your regular provider.